Health
Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer – EurekAlert
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung…
IMAGE: Tina Cascone, M.D., Ph.D.
view more
Credit: MD Anderson Cancer Center
HOUSTON — The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory. Researchers from The University of Texas…
-
Business24 hours agoWhat I’d buy before the ASX rebounds: 3 high-conviction share picks
-
Noosa News12 hours agoMotorbike rider dies after car collision at Kidaman Creek, west of Sunshine Coast
-
General13 hours agoDemocratic senators want an investigation into potential market manipulation from Trump’s inner circle
-
Noosa News22 hours agoMan shot in the leg during attempted break-in at Beenleigh, Queensland